Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 14/20 | 0.68 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26120223 | 0.91 | PDK2 (0.72) | PDK2PTPRCTSHRCA12CA1 | |
| SCHEMBL4914219 | 0.84 | PDK2 (0.63) | PDK2PTPRCTSHREGFRCA12 | |
| SCHEMBL30571998 | 0.83 | PDK2 (0.55) | PDK2PTPRCHTR7HTR2B | |
| SCHEMBL4915761 | 0.83 | PDK2 (0.55) | PDK2PTPRCHTR7HTR2B | |
| SCHEMBL13128005 | 0.81 | PDK2 (1.00) | PDK2 | |
| SCHEMBL4910149 | 0.80 | PDK2 (0.59) | PDK2TSHREGFRCA12CA1 | |
| SCHEMBL30571665 | 0.80 | PDK2 (0.70) | PDK2PTPRCTSHRCA12CA1 | |
| SCHEMBL26120111 | 0.80 | PDK2 (0.70) | PDK2PTPRCTSHRCA12CA1 | |
| SCHEMBL21135534 | 0.79 | PDK2 (0.61) | PDK2TSHREGFRCA12CA1 | |
| SCHEMBL4918215 | 0.79 | PDK2 (0.61) | PDK2PTPRCTSHREGFRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | ASTELLAS PHARMA INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
| EP-1716867-A1 | PREVENTIVES FOR MIGRAINE | Astellas Pharma Inc. (JP) | 2006-11-02 | — | — | EP | disclosed |
| CN-1842517-A | Fluorene derivatives | ASTELLAS PHARMA INC (JP) | 2006-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PDK2 3616/4885PTPRC 2222/4885TSHR 3056/4885 |
| US-20080161419-A1 | Prophylactic Antimigraine Agents | HTR2B, HTR7, HTR1A | PDK2 4410/4885PTPRC 2235/4885TSHR 730/4885 |
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | PDK2 4775/4885PTPRC 2610/4885TSHR 306/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | PDK2 4110/4885PTPRC 1236/4885TSHR 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.